Literature DB >> 15024692

High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta.

Wayne A Cabral1, Joan C Marini.   

Abstract

Individuals with mosaicism for the autosomal dominant bone dysplasia osteogenesis imperfecta (OI) are generally identified by having more than one affected child. The mosaic carriers have both normal and mutant cell populations in somatic and germline tissues but are unaffected or minimally affected by the type I collagen mutation that manifests clinically in their heterozygous offspring. We determined the proportion of mutant osteoblasts in skeletal tissue of two mosaic carriers who each have a COL1A1 mutation in a high proportion of dermal fibroblasts. Both carriers had normal height and bone histology; the first carrier had normal lumbar spine measurements (L1-L4), as determined by dual-energy x-ray absorptiometry (Z = +1.17). In cultured cells from the first carrier, studied by labeled PCR and single-cell PCR over successive passages, the collagen mutation was present in 85% of fibroblasts and 50% and 75% of osteoblasts from her right iliac crest and left patella, respectively, with minimal selection. The second carrier was studied by PCR amplification of DNA from autopsy paraffin blocks. The proportion of heterozygous cells was 40% in calvarium, 65% in tracheal ring, and 70% in aorta. Thus, in OI, substantially normal skeletal growth, density, and histology are compatible with a 40%-75% burden of osteoblasts heterozygous for a COL1A1 mutation. These data are encouraging for mesenchymal stem-cell transplantation, since mosaic carriers are a naturally occurring model for cell therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024692      PMCID: PMC1181952          DOI: 10.1086/383252

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  34 in total

1.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging.

Authors:  M Oyama; A Tatlock; S Fukuta; K Kavalkovich; K Nishimura; B Johnstone; P D Robbins; C H Evans; C Niyibizi
Journal:  Gene Ther       Date:  1999-03       Impact factor: 5.250

4.  Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta.

Authors:  E M Horwitz; D J Prockop; P L Gordon; W W Koo; L A Fitzpatrick; M D Neel; M E McCarville; P J Orchard; R E Pyeritz; M K Brenner
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

5.  Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep.

Authors:  T C Mackenzie; A W Flake
Journal:  Blood Cells Mol Dis       Date:  2001 May-Jun       Impact factor: 3.039

6.  Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.

Authors:  S M Devine; A M Bartholomew; N Mahmud; M Nelson; S Patil; W Hardy; C Sturgeon; T Hewett; T Chung; W Stock; D Sher; S Weissman; K Ferrer; J Mosca; R Deans; A Moseley; R Hoffman
Journal:  Exp Hematol       Date:  2001-02       Impact factor: 3.084

Review 7.  Approaches for skeletal gene therapy.

Authors:  Christopher Niyibizi; Corey J Wallach; Zhibao Mi; Paul D Robbins
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2002       Impact factor: 1.807

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

Review 9.  Mechanisms and consequences of somatic mosaicism in humans.

Authors:  Hagop Youssoufian; Reed E Pyeritz
Journal:  Nat Rev Genet       Date:  2002-10       Impact factor: 53.242

10.  Human bone cells in vitro.

Authors:  P G Robey; J D Termine
Journal:  Calcif Tissue Int       Date:  1985-09       Impact factor: 4.333

View more
  14 in total

1.  Local transplantation is an effective method for cell delivery in the osteogenesis imperfecta murine model.

Authors:  Penelope Pauley; Brya G Matthews; Liping Wang; Nathaniel A Dyment; Igor Matic; David W Rowe; Ivo Kalajzic
Journal:  Int Orthop       Date:  2014-01-03       Impact factor: 3.075

2.  Ehlers-Danlos arthrochalasia type (VIIA-B)--expanding the phenotype: from prenatal life through adulthood.

Authors:  M Klaassens; E Reinstein; Y Hilhorst-Hofstee; J J P Schrander; F Malfait; H Staal; L C ten Have; J Blaauw; H C J Roggeveen; D Krakow; A De Paepe; M A M van Steensel; G Pals; J M Graham; C T R M Schrander-Stumpel
Journal:  Clin Genet       Date:  2011-08-24       Impact factor: 4.438

Review 3.  Therapeutic application of mesenchymal stem cells in bone and joint diseases.

Authors:  Yi Liu; Jianmei Wu; Youming Zhu; Jinxiang Han
Journal:  Clin Exp Med       Date:  2012-11-03       Impact factor: 3.984

Review 4.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

5.  Potential implications of cell therapy for osteogenesis imperfecta.

Authors:  Christopher Niyibizi; Feng Li
Journal:  Int J Clin Rheumtol       Date:  2009-02-01

6.  Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta.

Authors:  Joel R Chamberlain; David R Deyle; Ulrike Schwarze; Peirong Wang; Roli K Hirata; Yi Li; Peter H Byers; David W Russell
Journal:  Mol Ther       Date:  2007-10-23       Impact factor: 11.454

7.  A scoring system for the assessment of clinical severity in osteogenesis imperfecta.

Authors:  Mona S Aglan; Laila Hosny; Rasha El-Houssini; Sawsan Abdelhadi; Fadia Salem; Rokia A S Elbanna; Seham A Awad; Moushira E Zaki; Samia A Temtamy
Journal:  J Child Orthop       Date:  2012-02-08       Impact factor: 1.548

8.  In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.

Authors:  Cristina Panaroni; Roberta Gioia; Anna Lupi; Roberta Besio; Steven A Goldstein; Jaclynn Kreider; Sergey Leikin; Juan Carlos Vera; Edward L Mertz; Egon Perilli; Fabio Baruffaldi; Isabella Villa; Aurora Farina; Marco Casasco; Giuseppe Cetta; Antonio Rossi; Annalisa Frattini; Joan C Marini; Paolo Vezzoni; Antonella Forlino
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

9.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

10.  Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta.

Authors:  Julie Rousseau; Roberta Gioia; Pierre Layrolle; Blandine Lieubeau; Dominique Heymann; Antonio Rossi; Joan C Marini; Valerie Trichet; Antonella Forlino
Journal:  Eur J Hum Genet       Date:  2013-09-11       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.